BioSpace News Archive

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.

Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2019 second quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, July 23, 2019, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results

Company to showcase market leadership with comprehensive Synapse portfolio, robust AI capabilities, and #AskIndustry panel participation

Actinium Pharmaceuticals, Inc. announced its presence at the upcoming SNMMI or Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting being held June 22nd – 25th in Anaheim, California.

Vaxart, Inc. announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, 2019 in San Francisco, California.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announced a direct investment of $10 million from Taiho Ventures, LLC to fund the discovery and development of novel gut-targeted, small molecule approaches in oncology.

WellCare Health Plans, Inc. CEO Ken Burdick has won a Glassdoor Employees’ Choice Award honoring the Top CEOs in 2019.

A new survey from Health Union reveals skin cancer recurrences are often linked to a bevy of risk factors and lower quality of life